Target Name: MIR29A
NCBI ID: G407021
Other Name(s): MIRN29A | microRNA 29a | MicroRNA 29a | miRNA29A | hsa-miR-29a-3p | hsa-mir-29 | hsa-miR-29a-5p | MIRN29 | hsa-mir-29a | mir-29a

MIR29A: A Potential Drug Target and Biomarker

MIR29A, a gene located on chromosome 6p21.2, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function and regulation have been extensively studied, and its potential as a drug target continue to grow.

MIR29A is a non-coding RNA molecule that is composed of 29 exons. It is located in the 6p21.2 region of the chromosome, which is known as the gene therapy window. This region is associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. MIR29A has been shown to be involved in the regulation of cellular processes, including cell adhesion, migration, and survival.

One of the most promising aspects of MIR29A is its potential as a drug target. MIR29A has been shown to play a role in the regulation of T cell development and function. It has been shown to be involved in the development and maintenance of regulatory T cells, which are a crucial part of the immune system. MIR29A has also been shown to play a role in the regulation of cancer cell growth and survival.

In addition to its potential as a drug target, MIR29A has also been identified as a potential biomarker for various diseases. Its expression has been shown to be associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that MIR29A may be a useful biomarker for these diseases, and that its levels may be able to be used as a diagnostic tool.

The discovery and characterization of MIR29A as a potential drug target and biomarker has important implications for the development of new treatments for various diseases. With further research, it is possible that MIR29A may be isolated and used as a drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its potential as a biomarker may also be used to diagnose and monitor these diseases.

In conclusion, MIR29A is a gene that has been extensively studied for its potential as a drug target and biomarker. Its function and regulation have been extensively studied, and its potential as a drug target and biomarker continue to grow. Further research is needed to fully understand its function and potential as a drug target and biomarker. If its potential is valid, MIR29A may be isolated and used as a new treatment option for various diseases.

Protein Name: MicroRNA 29a

More Common Targets

MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144 | MIR3145 | MIR3146 | MIR3147 | MIR3147HG | MIR3148 | MIR3149 | MIR3150A | MIR3150B | MIR3151 | MIR3152 | MIR3153 | MIR3154 | MIR3155A | MIR3155B | MIR3156-1 | MIR3156-2 | MIR3156-3 | MIR3157 | MIR3158-1 | MIR3158-2 | MIR3159 | MIR3160-1 | MIR3160-2 | MIR3161 | MIR3162 | MIR3163 | MIR3164 | MIR3165 | MIR3166 | MIR3167 | MIR3168 | MIR3169 | MIR3170 | MIR3171 | MIR3171HG